Table 4.
Analysis of factors affecting one-year tumor recurrence rate in patients with HCC.
| Variables | One-yr recurrence n (%) | P value | |
|
| |||
| Gender | Female (n = 42) | 10 (24) | .3 |
| Male (n = 241) | 43 (18) | ||
|
| |||
| Age | ≤ 60 years (n = 184) | 34 (18) | .8 |
| > 60 years (n = 99) | 19 (19) | ||
|
| |||
| AFP > 30 ng/mL at OLT | No (n = 201) | 30 (15) | .01 |
| Yes (n = 78) | 22 (28) | ||
|
| |||
| Viral infection | HCV-positive (n = 152) | 30 (20) | .8 |
| HBV-positive (n = 70) | 13 (19) | ||
| HCV, HBV-positive (n = 13) | 3 (23) | ||
| HCV, HBV-negative (n = 48) | 7 (15) | ||
|
| |||
| Down-staging to MC | No (n = 243) | 46 (19) | .8 |
| Yes (n = 39) | 7 (18) | ||
|
| |||
| Preoperative MC | Fulfilled (n = 224) | 44 (20) | .4 |
| Not fulfilled (n = 59) | 9 (15) | ||
|
| |||
| Preoperative up-to-seven | Fulfilled (n = 267) | 51 (19) | .7 |
| Not fulfilled (n = 16) | 2 (12) | ||
|
| |||
| Pre-OLT treatments | No (n = 53) | 4 (7) | .02 |
| Yes (n = 222) | 47 (21) | ||
|
| |||
| Histological MC | Fulfilled (n = 208) | 36 (17) | .3 |
| Not fulfilled (n = 75) | 17 (23) | ||
|
| |||
| Histological up-to-seven | Fulfilled (n = 249) | 45 (18) | .4 |
| Not fulfilled (n = 34) | 8 (23) | ||
|
| |||
| Grading | G0–G2 (n = 143) | 23 (16) | .2 |
| G3–G4 (n = 140) | 30 (21) | ||
|
| |||
| Microvascular invasion | No (n = 166) | 25 (15) | .06 |
| Yes (n = 117) | 28 (24) | ||
|
| |||
| Macrovascular invasion | No (n = 280) | 52 (19) | .4 |
| Yes (n = 3) | 1 (33) | ||
|
| |||
| Post-OLT m-TOR inhibitors | No (n = 240) | 47 (20) | .3 |
| Yes (n = 43) | 6 (14) | ||
OLT: orthotopic liver transplantation. HCC: hepatocellular carcinoma. AFP: alpha-fetoprotein. MC: Milan criteria. M-TOR: Mammalian Target Of Rapamycin.